CRISPR and Genome Editing – News and Features

A study found a gene in human cytomegalovirus (HCMV) that can block immune responses needed for an effective HIV vaccine. This discovery could improve future vaccine designs for HIV and other diseases.

Researchers have discovered that a protein complex that helps fight cancer cells also slows the growth of tuberculosis – a finding that could mean better treatments for both diseases.

This article highlights several inspiring men and women working across academia and industry who are breaking barriers and regaining ownership of their own narratives.

Researchers discovered that the CRISPR-Cas10 system not only cuts viral DNA but also produces toxic cyclic-oligoadenylates (cOAs) to stop viral spread. This dual mechanism enhances bacterial defense against infections.

A new mouse study shows how a new tool can deliver genetic material to edit faulty genes in developing fetal brain cells.

Researchers expand on their phase one study demonstrating a single treatment with a CRISPR-Cas9-based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema.

We reached out to start-ups at ELRIG Drug Discovery 2024 to see how AI and bioengineering can be applied in biotech and drug discovery.

What keeps some immune systems youthful and effective in warding off age-related diseases? A mouse study provides new insights.

Researchers from NYU have discovered that gene activity significantly influences genome motions. By employing CRISPR and advanced microscopy, they found that active genes stir the genome's organization.

In this interview, Dr. Graeme Daniels, Sphere Fluidics, shares how advanced microfluidics are set to revolutionize biotherapeutic workflows and discusses the technology's future potential in broader applications, including cell and gene therapy.